Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venoven...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Antimicrobial agents and chemotherapy Ročník 54; číslo 11; s. 4939
Hlavní autori: Layeux, Brice, Taccone, Fabio Silvio, Fagnoul, David, Vincent, Jean-Louis, Jacobs, Frédérique
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.11.2010
Predmet:
Aged
Amikacin - therapeutic use
Anti-Bacterial Agents - therapeutic use
C-Reactive Protein - metabolism
Creatinine - metabolism
Female
Humans
Male
Middle Aged
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - pathogenicity
Sepsis - drug therapy
Sepsis - metabolism
Sepsis - microbiology
ISSN:1098-6596, 1098-6596
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venovenous hemodiafiltration (CVVHDF) provided no deterioration in renal function after treatment. High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens.
Bibliografia:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1098-6596
1098-6596
DOI:10.1128/AAC.00441-10